WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018058258) RECOMBINANT ONCOLYTIC VIRUSES FOR CANCER THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/058258    International Application No.:    PCT/CA2017/051171
Publication Date: 05.04.2018 International Filing Date: 02.10.2017
IPC:
C12N 15/863 (2006.01), A61K 35/768 (2015.01), A61P 35/00 (2006.01), C07H 21/04 (2006.01), C12N 15/39 (2006.01), C12N 15/85 (2006.01), C12N 15/86 (2006.01), C12N 5/10 (2006.01), C12N 7/01 (2006.01)
Applicants: UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street R. Fraser Elliott Building - Room 1S-417 Toronto, Ontario M5G 2C4 (CA).
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. [CA/CA]; 401 Smyth Road Ottawa, Ontario K1H 8L1 (CA)
Inventors: MCCART, Judith, Andrea; (CA).
STOJDL, David, Francis; (CA).
HO, Tiffany, Yun-Yee; (CA)
Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.; 40th Floor 40 King Street West Toronto, Ontario M5H 3Y2 (CA)
Priority Data:
62/402,574 30.09.2016 US
Title (EN) RECOMBINANT ONCOLYTIC VIRUSES FOR CANCER THERAPY
(FR) VIRUS ONCOLYTIQUES RECOMBINÉS POUR LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes.
(FR)L'invention concerne un poxvirus oncolytique recombiné comprenant un virus de la vaccine comprenant un ou plusieurs gènes immunomodulateurs inactivés choisis parmi NIL, K1L, K3L, A46R et/ou A52R, comprenant en outre éventuellement des gènes TK et/ou VGF inactivés. L'invention concerne également des procédés et l'utilisation de ces poxvirus oncolytiques recombinés dans une virothérapie oncolytique. L'invention concerne également des constructions de vecteur permettant de générer des poxvirus oncolytiques recombinés comprenant, par exemple, des virus de la vaccine qui ont un ou plusieurs gènes immunomodulateurs inactivés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)